Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies.
The use of DNA vector-based short hairpin (sh)RNA for RNA interference shows promise as a precise means for the disruption of gene expression to achieve a therapeutic effect. The in vivo usage of shRNA therapeutics in cancer is limited by obstacles related to effective delivery into the nuclei of target cancer cells. Nonviral delivery vehicles that are relevant for shRNA delivery into humans belong to a group of substances about which significant preclinical data has been amassed to show an acceptable safety profile, resistance to immune defenses and good transfection efficiency. Here, we review the most promising current nonviral gene delivery vehicles with a focus on their potential use in cancer shRNA therapeutics.
Vorhies
John S
JS
Mary Crowley Medical Research Center, 1717 Main St, Suite 6000, Dallas, TX 75201, USA. jsvorhies@gmail.com
Nemunaitis
John
J
D001704:Biopolymers / Q000008:administration & dosage / Q000493:pharmacokinetics; D002412:Cations; D002467:Cell Nucleus / Q000378:metabolism; D016503:Drug Delivery Systems; D004705:Endocytosis; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008024:Ligands; D008081:Liposomes / Q000008:administration & dosage; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D014677:Pharmaceutical Vehicles; D011108:Polymers / Q000008:administration & dosage / Q000493:pharmacokinetics; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use
D001704:Biopolymers; D002412:Cations; D008024:Ligands; D008081:Liposomes; D009363:Neoplasm Proteins; D014677:Pharmaceutical Vehicles; D011108:Polymers; D034741:RNA, Small Interfering